Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Summary
Novartis (NVS, Financial) has announced a strategic agreement to acquire Regulus Therapeutics (RGLS), offering an initial payment of $7.00 per share in cash. This acquisition, amounting to approximately $0.8 billion, underscores Novartis commitment to enhancing its biopharmaceutical offerings and expanding its therapeutic capabilities. The investment community offers valuable insights, with 11 analysts providing one-year price targets for Novartis AG (NVS, Financial). This average target suggests a minor downside of 2.09% from the current stock price of $114.29, presenting a cautious but balanced outlook. This scale ranges from 1, indicating Strong Buy, to 5, signifying a Sell recommendation, which highlights a market sentiment that suggests stability for Novartis.